肝内胆管癌及其MRI鉴别诊断:放射科医生应如何评估MR特征
研究纳入88例组织学确诊的肝内胆管癌(ICC)患者,以86例结直肠癌肝内转移、35例胆管周围转移、62例肝细胞癌、18例混合型肝细胞-胆管癌和26例肝血管瘤为对照组,按LI-RADS v2018评估MRI特征。结果显示T1WI和T2WI信号强度、扩散受限、移行期和肝胆期表现可显著区分肿块型ICC与各对照组,而动脉期可区分肿块型ICC与肝细胞癌及混合型肝细胞-胆管癌,门脉期可区分肿块型ICC与结直肠癌肝转移、肝细胞癌及混合型肝细胞-胆管癌;胆管周围浸润型ICC与胆管周围转移之间无任何MR特征可区分。
要点
- 肿块型ICC与肝细胞癌、混合型肝细胞-胆管癌的鉴别可借助T1WI/T2WI信号、扩散受限、移行期、肝胆期及动脉期表现。
- 肿块型ICC与结直肠癌肝转移的鉴别可借助T1WI/T2WI信号、扩散受限、移行期、肝胆期及门脉期表现。
- 胆管周围浸润型ICC与胆管周围转移之间无任何MR特征可显著区分。
核心结论
- T1WI和T2WI信号强度、扩散受限、移行期和肝胆期表现可显著区分肿块型ICC与各模拟病变,动脉期可显著区分肿块型ICC与肝细胞癌及混合型肝细胞-胆管癌,门脉期可显著区分肿块型ICC与结直肠癌肝转移、肝细胞癌及混合型肝细胞-胆管癌。
研究设计与样本
- 研究纳入88例组织学确诊的ICC患者,其中肿块型61例、胆管周围浸润型23例、胆管内生长型4例;对照组包括86例连续结直肠癌肝内转移患者(A组)、35例连续胆管周围转移患者(B组)、62例连续肝细胞癌患者(C组)、18例连续混合型肝细胞-胆管癌患者(D组)和26例连续肝血管瘤患者(E组)。
关键影像表现/征象
- 所有病变均按LI-RADS 2018版评估MRI特征,使用肝特异性钆塞酸二钠(Gd-EOB-DTPA,Primovist,拜耳先灵制药,德国)增强扫描。
诊断标准与关键数值
- 采用卡方检验分析分类变量百分比差异,采用非参数Kruskal-Wallis检验分析连续变量中位数差异,并按Benjamini-Hochberg法进行多重检验的错误发现率校正。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common type of primary hepatic malignancy. Aim of this work is to analyse the features of ICC and its differential diagnosis at MRI, assessing two categories intraparenchymal and peribiliary lesions.
METHODS: The study population included 88 patients with histological diagnosis of ICCs: 61 with mass-forming type, 23 with periductal-infiltrating tumours and 4 with intraductal-growing type. As a control study groups, we identified: 86 consecutive patients with liver colorectal intrahepatic metastases (mCRC) (groups A); 35 consecutive patients with peribiliary metastases (groups B); 62 consecutive patients (groups C) with hepatocellular carcinoma (HCC); 18 consecutive patients (groups D) with combined hepatocellular cholangiocarcinoma (cHCC-CCA); and 26 consecutive patients (groups E) with hepatic hemangioma. For all lesions, magnetic resonance (MR) features were assessed according to Liver Imaging Reporting and Data System (LI-RADS) version 2018. The liver-specific gadolinium ethoxybenzyl dimeglumine-EOB (Primovist, Bayer Schering Pharma, Germany), was employed. Chi-square test was employed to analyse differences in percentage values of categorical variable, while the nonparametric Kruskal-Wallis test was used to test for statistically significant differences between the median values of the continuous variables. However, false discovery rate adjustment according to Benjamin and Hochberg for multiple testing was considered.
RESULTS: T1- and T2-weighted signal intensity (SI), restricted diffusion, transitional phase (TP) and hepatobiliary phase (HP) aspects allowed the differentiation between study group (mass-forming ICCs) and each other control group (A, C, D, E) with statistical significance, while arterial phase (AP) appearance allowed the differentiation between study group and the control groups C and D with statistical significance and PP appearance allowed the differentiation between study group and the control groups A, C and D with statistical significance. Instead, no MR feature allowed the differentiation between study group (periductal-infiltrating type) and control group B.
CONCLUSION: T1 and T2 W SI, restricted diffusion, TP and HP appearance allowed the differentiation between mass-forming ICCs and mimickers with statistical significance, while AP appearance allowed the differentiation between study group and the control groups C and D with statistical significance and PP appearance allowed the differentiation between study group and the control groups A, C and D.
引用
- Granata, Grassi, Fusco, et al. Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features. Radiol Med. 2021. PMID: 34843029. doi:10.1007/s11547-021-01428-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。